News

GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors.

06/13/2025

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2.

05/19/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is GT Biopharma, Inc. (GTBP) a buy, sell, or hold?

GT Biopharma, Inc. (GTBP) can sell. Click on Rating Page for detail.

What is GT Biopharma, Inc.'s stock price?

The price of GT Biopharma, Inc. (GTBP) is 2.78 and it was updated on 2025-07-03 11:00:21.

Is GT Biopharma, Inc. (GTBP) overvalued or undervalued?

Currently GT Biopharma, Inc. (GTBP) is in undervalued.

News

From:

To:

News
GT Biopharma Appoints New Member to its Board of Directors SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. Wed, May. 14, 2025
GT Biopharma Announces Exercise of Warrants SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK”) cell engager platform, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 302,069 shares of its common stock having an exercise price of $4.35 per share, originally issued in May 2024. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-280326). The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $0.7 million, prior to deducting placement agent fees and offering expenses payable by the Company. Tue, Feb. 25, 2025
GT Biopharma Reports Third Quarter 2024 Financial Results SAN FRANCISCO, CALIFORNIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced third quarter 2024 financial results for the period ended September 30, 2024. Thu, Nov. 14, 2024
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School2 and GT Biopharma's Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York, NY. Company management will also be participating in 1x1 meetings during the event. Thu, Sep. 26, 2024
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced it will host a virtual KOL event on Thursday, October 10, 2024 at 12:00 PM ET. To register, click here. Tue, Sep. 24, 2024

Transcripts

Transcipts Data
GT Biopharma, Inc. (GTBP) on Q2 2021 Results - Earnings Call Transcript SA Transcripts Fri, Aug. 13, 2021

SEC Filings

SEC Filings
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 06/11/2025
GT Biopharma, Inc. (GTBP) - DEFA14A SEC Filings 06/11/2025
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 06/11/2025
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/11/2025
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 06/03/2025
GT Biopharma, Inc. (GTBP) - SCHEDULE 13G/A SEC Filings 06/02/2025
GT Biopharma, Inc. (GTBP) - PRE 14A SEC Filings 05/30/2025
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 05/29/2025
GT Biopharma, Inc. (GTBP) - D SEC Filings 05/28/2025
GT Biopharma, Inc. (GTBP) - D SEC Filings 05/27/2025
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/27/2025
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/2025
GT Biopharma, Inc. (GTBP) - SCHEDULE 13G SEC Filings 05/14/2025
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/13/2025
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/05/2025
GT Biopharma, Inc. (GTBP) - 10-K/A - Current report SEC Filings 04/14/2025
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/04/2025
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 03/14/2025
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 03/14/2025
GT Biopharma, Inc. (GTBP) - D SEC Filings 03/07/2025
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 03/06/2025
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/26/2025
GT Biopharma, Inc. (GTBP) - RW SEC Filings 02/24/2025
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 02/21/2025
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 02/07/2025
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 01/27/2025
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/27/2025
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 12/23/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/27/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/21/2024
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/14/2024
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 10/21/2024
GT Biopharma, Inc. (GTBP) - SCHEDULE 13G/A SEC Filings 10/17/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/16/2024
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/14/2024
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 07/02/2024
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 07/01/2024
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 06/27/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/27/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/26/2024
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 06/20/2024
GT Biopharma, Inc. (GTBP) - DEFA14A SEC Filings 06/17/2024
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 06/13/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/07/2024
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 05/23/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/23/2024
GT Biopharma, Inc. (GTBP) - 424B5 SEC Filings 05/23/2024
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/30/2024
GT Biopharma, Inc. (GTBP) - DEFA14A SEC Filings 04/29/2024
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 04/29/2024
GT Biopharma, Inc. (GTBP) - ARS SEC Filings 04/29/2024
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/26/2024
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/14/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/01/2024
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/21/2023
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/04/2023
GT Biopharma, Inc. (GTBP) - DEFA14A SEC Filings 11/06/2023
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 11/06/2023
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/01/2023
GT Biopharma, Inc. (GTBP) - PRE 14A SEC Filings 10/27/2023
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 09/19/2023
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/22/2023
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 08/15/2023
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/07/2023
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/05/2023
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 06/21/2023
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/2023
GT Biopharma, Inc. (GTBP) - DEFR14A SEC Filings 05/05/2023
GT Biopharma, Inc. (GTBP) - DEFA14A SEC Filings 05/05/2023
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/04/2023
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 05/04/2023
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 05/01/2023
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 04/11/2023
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 04/10/2023
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/30/2023
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/28/2023
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 02/14/2023
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 02/01/2023
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/04/2023
GT Biopharma, Inc. (GTBP) - 424B5 SEC Filings 01/04/2023
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/13/2022
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/09/2022
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 10/31/2022
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 10/21/2022
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 10/13/2022
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/12/2022
GT Biopharma, Inc. (GTBP) - DEFA14A SEC Filings 10/04/2022
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/04/2022
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/30/2022
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 08/17/2022
GT Biopharma, Inc. (GTBP) - 8-K/A - Current report SEC Filings 08/17/2022
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/15/2022
GT Biopharma, Inc. (GTBP) - S-8 SEC Filings 07/25/2022
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 07/19/2022
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/14/2022
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 06/14/2022
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/10/2022
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/16/2022
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 04/29/2022
GT Biopharma, Inc. (GTBP) - PRE 14A SEC Filings 04/19/2022
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/28/2022
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/08/2022
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 03/03/2022
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 03/02/2022
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/18/2022
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 02/18/2022
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 02/14/2022
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 02/14/2022
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 01/28/2022
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 01/26/2022
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 01/18/2022
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 12/29/2021
GT Biopharma, Inc. (GTBP) - 10-Q/A - Quarterly Report SEC Filings 12/29/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/23/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/21/2021
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 12/15/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/26/2021
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 11/12/2021
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 11/12/2021
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/10/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/01/2021
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 10/07/2021
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 10/07/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/23/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/13/2021
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/23/2021
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 08/17/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/19/2021
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/17/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/29/2021
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 04/28/2021
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 04/27/2021
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 04/23/2021
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 04/23/2021
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 04/23/2021
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 04/22/2021
GT Biopharma, Inc. (GTBP) - POS AM SEC Filings 04/22/2021
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 04/22/2021
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 04/16/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/16/2021
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 04/16/2021
GT Biopharma, Inc. (GTBP) - NT 10-K - Current report SEC Filings 03/31/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/22/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/18/2021
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 02/17/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/17/2021
GT Biopharma, Inc. (GTBP) - 424B4 SEC Filings 02/12/2021
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 02/11/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/11/2021
GT Biopharma, Inc. (GTBP) - 424B4 SEC Filings 02/11/2021
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 02/10/2021
GT Biopharma, Inc. (GTBP) - S-1MEF SEC Filings 02/10/2021
GT Biopharma, Inc. (GTBP) - CERT SEC Filings 02/10/2021
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 02/09/2021
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 02/09/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/09/2021
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/08/2021
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 02/08/2021
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 02/08/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/08/2021
GT Biopharma, Inc. (GTBP) - 8-A12B SEC Filings 02/08/2021
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/05/2021
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 02/02/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/02/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/01/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/19/2021
GT Biopharma, Inc. (GTBP) - DEF 14C SEC Filings 01/14/2021
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/31/2020
GT Biopharma, Inc. (GTBP) - PRE 14C SEC Filings 12/30/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/28/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/23/2020
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/23/2020
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/18/2020
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 12/16/2020
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/15/2020
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 12/11/2020
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 11/19/2020
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/13/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/09/2020
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 11/09/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/04/2020
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 11/04/2020
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 10/07/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/06/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/22/2020
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 09/22/2020
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 08/18/2020
GT Biopharma, Inc. (GTBP) - 10-Q/A - Quarterly Report SEC Filings 08/18/2020
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 08/14/2020
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/14/2020
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 07/30/2020
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 07/29/2020
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 07/28/2020
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 07/24/2020
GT Biopharma, Inc. (GTBP) - D/A SEC Filings 07/23/2020
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 07/22/2020
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 07/14/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/09/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/23/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/19/2020
GT Biopharma, Inc. (GTBP) - D SEC Filings 06/12/2020
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 06/10/2020
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 06/04/2020
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/29/2020
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 05/18/2020
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/2020
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 05/14/2020
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/27/2020
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/04/2020
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 01/16/2020
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/14/2019
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 10/03/2019
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 10/02/2019
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 09/26/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/24/2019
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 09/20/2019
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 09/13/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/23/2019
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 08/16/2019
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/14/2019
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 07/15/2019
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 07/11/2019
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 07/08/2019
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 07/02/2019
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 06/21/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/24/2019
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/19/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/05/2019
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/29/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/22/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/21/2019
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 03/19/2019
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 03/12/2019
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 03/05/2019
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 02/28/2019
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 02/14/2019
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/13/2019
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 02/13/2019
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 02/13/2019
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/12/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/06/2019
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/05/2019
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 01/29/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/07/2019
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/15/2018
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/14/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/01/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/16/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/12/2018
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 10/09/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/28/2018
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 09/21/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/07/2018
GT Biopharma, Inc. (GTBP) - D SEC Filings 08/17/2018
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/14/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/03/2018
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 08/03/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/05/2018
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/14/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/27/2018
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 03/23/2018
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 03/23/2018
GT Biopharma, Inc. (GTBP) - S-3/A SEC Filings 03/21/2018
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 03/21/2018
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 03/16/2018
GT Biopharma, Inc. (GTBP) - S-3/A SEC Filings 03/15/2018
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 03/15/2018
GT Biopharma, Inc. (GTBP) - 8-K/A - Current report SEC Filings 03/15/2018
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 03/12/2018
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 03/01/2018
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/01/2018
GT Biopharma, Inc. (GTBP) - 10-Q/A - Quarterly Report SEC Filings 02/28/2018
GT Biopharma, Inc. (GTBP) - 10-K/A - Current report SEC Filings 02/28/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/21/2018
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/07/2018
GT Biopharma, Inc. (GTBP) - D SEC Filings 02/06/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/23/2018
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/16/2018
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 12/04/2017
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/01/2017
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 12/01/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/16/2017
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 11/14/2017
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/14/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/12/2017
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 10/10/2017
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 09/20/2017
GT Biopharma, Inc. (GTBP) - D SEC Filings 09/14/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/05/2017
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/11/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/25/2017
GT Biopharma, Inc. (GTBP) - RW SEC Filings 07/24/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/26/2017
GT Biopharma, Inc. (GTBP) - DEF 14C SEC Filings 05/12/2017
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 05/09/2017
GT Biopharma, Inc. (GTBP) - PRER14C SEC Filings 05/05/2017
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 04/28/2017
GT Biopharma, Inc. (GTBP) - PRER14C SEC Filings 04/24/2017
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 04/20/2017
GT Biopharma, Inc. (GTBP) - PRER14C SEC Filings 04/14/2017
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 04/06/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/03/2017
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/31/2017
GT Biopharma, Inc. (GTBP) - PRE 14C SEC Filings 03/24/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/23/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/02/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/17/2017
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/13/2017
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/10/2017
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 02/10/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/09/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/03/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/27/2017
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 01/24/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/20/2017
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/13/2017
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 12/28/2016
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 11/21/2016
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/14/2016
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 10/31/2016
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 10/03/2016
GT Biopharma, Inc. (GTBP) - S-1/A SEC Filings 08/25/2016
GT Biopharma, Inc. (GTBP) - S-1 SEC Filings 08/24/2016
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/10/2016
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/09/2016
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/17/2016
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/03/2016
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/13/2016
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 04/05/2016
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 04/05/2016
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/30/2016
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 03/02/2016
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 02/23/2016
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/19/2016
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 02/18/2016
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 02/12/2016
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 02/09/2016
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 01/26/2016
GT Biopharma, Inc. (GTBP) - SC 13D/A SEC Filings 01/26/2016
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 01/25/2016
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 01/25/2016
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/22/2016
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/08/2016
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/13/2015
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/26/2015
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/08/2015
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/14/2015
GT Biopharma, Inc. (GTBP) - D SEC Filings 07/27/2015
GT Biopharma, Inc. (GTBP) - DEF 14C SEC Filings 05/19/2015
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/14/2015
GT Biopharma, Inc. (GTBP) - PRE 14C SEC Filings 05/08/2015
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/31/2015
GT Biopharma, Inc. (GTBP) - D SEC Filings 03/16/2015
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/13/2015
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/11/2015
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/12/2015
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 01/08/2015
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 01/08/2015
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 12/17/2014
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 12/12/2014
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 12/10/2014
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/20/2014
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 11/18/2014
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/10/2014
GT Biopharma, Inc. (GTBP) - D SEC Filings 07/31/2014
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/30/2014
GT Biopharma, Inc. (GTBP) - NT 10-K - Current report SEC Filings 04/01/2013
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/13/2013
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/12/2012
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/21/2012
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 11/15/2012
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/06/2012
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/24/2012
GT Biopharma, Inc. (GTBP) - 10-Q/A - Quarterly Report SEC Filings 09/13/2012
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/20/2012
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 08/14/2012
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 05/30/2012
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/21/2012
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 05/15/2012
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 04/16/2012
GT Biopharma, Inc. (GTBP) - NT 10-K - Current report SEC Filings 03/30/2012
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/21/2011
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 11/15/2011
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/01/2011
GT Biopharma, Inc. (GTBP) - 10-Q/A - Quarterly Report SEC Filings 09/12/2011
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 09/01/2011
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/31/2011
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/22/2011
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 08/15/2011
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 07/14/2011
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 07/13/2011
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 07/12/2011
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 07/12/2011
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/12/2011
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 07/11/2011
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/07/2011
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 07/07/2011
GT Biopharma, Inc. (GTBP) - PRE 14A SEC Filings 07/01/2011
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/01/2011
GT Biopharma, Inc. (GTBP) - S-8 SEC Filings 06/29/2011
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 05/24/2011
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/16/2011
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/31/2011
GT Biopharma, Inc. (GTBP) - SC 13D/A SEC Filings 03/29/2011
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/15/2011
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 02/08/2011
GT Biopharma, Inc. (GTBP) - DEF 14C SEC Filings 01/20/2011
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 01/19/2011
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 01/19/2011
GT Biopharma, Inc. (GTBP) - 3/A SEC Filings 01/19/2011
GT Biopharma, Inc. (GTBP) - PRE 14C SEC Filings 01/07/2011
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 12/17/2010
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 12/06/2010
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/12/2010
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 09/02/2010
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 08/30/2010
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/16/2010
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/20/2010
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 07/12/2010
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/17/2010
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/14/2010
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 04/06/2010
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 04/06/2010
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/30/2010
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 03/25/2010
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 03/22/2010
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/15/2010
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/05/2010
GT Biopharma, Inc. (GTBP) - SC 13D SEC Filings 02/22/2010
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/16/2010
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/16/2010
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/20/2010
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 12/09/2009
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 11/16/2009
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/09/2009
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 09/25/2009
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/23/2009
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 05/15/2009
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/13/2009
GT Biopharma, Inc. (GTBP) - NT 10-K/A - Current report SEC Filings 04/01/2009
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/01/2009
GT Biopharma, Inc. (GTBP) - NT 10-K - Current report SEC Filings 03/31/2009
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/13/2009
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/18/2008
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 12/18/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/10/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/09/2008
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 11/14/2008
GT Biopharma, Inc. (GTBP) - SC 13D/A SEC Filings 10/06/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/10/2008
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 08/19/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/18/2008
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 08/14/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/16/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/30/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/24/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/17/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/13/2008
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 05/20/2008
GT Biopharma, Inc. (GTBP) - NT 10-Q - Quarterly Report SEC Filings 05/15/2008
GT Biopharma, Inc. (GTBP) - 10KSB SEC Filings 04/11/2008
GT Biopharma, Inc. (GTBP) - NT 10-K - Current report SEC Filings 03/31/2008
GT Biopharma, Inc. (GTBP) - 5 SEC Filings 02/08/2008
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/27/2007
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 11/15/2007
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 11/14/2007
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 11/13/2007
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/25/2007
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/16/2007
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/27/2007
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 09/19/2007
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 08/15/2007
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 08/14/2007
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 06/01/2007
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 05/29/2007
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 05/29/2007
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 05/21/2007
GT Biopharma, Inc. (GTBP) - 10KSB/A SEC Filings 05/21/2007
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 05/15/2007
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 05/11/2007
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 05/11/2007
GT Biopharma, Inc. (GTBP) - POS AM SEC Filings 05/09/2007
GT Biopharma, Inc. (GTBP) - 8-K/A - Current report SEC Filings 05/03/2007
GT Biopharma, Inc. (GTBP) - 10KSB SEC Filings 04/17/2007
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/16/2007
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/06/2007
GT Biopharma, Inc. (GTBP) - NT 10-K - Current report SEC Filings 04/02/2007
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 02/28/2007
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/14/2007
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 02/14/2007
GT Biopharma, Inc. (GTBP) - EFFECT SEC Filings 02/13/2007
GT Biopharma, Inc. (GTBP) - SB-2/A SEC Filings 02/09/2007
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 02/09/2007
GT Biopharma, Inc. (GTBP) - SB-2/A SEC Filings 01/23/2007
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 01/19/2007
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 01/19/2007
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/18/2007
GT Biopharma, Inc. (GTBP) - SB-2/A SEC Filings 01/11/2007
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 12/20/2006
GT Biopharma, Inc. (GTBP) - SB-2 SEC Filings 12/08/2006
GT Biopharma, Inc. (GTBP) - S-8 SEC Filings 11/17/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/15/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 11/15/2006
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 11/14/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/13/2006
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 11/08/2006
GT Biopharma, Inc. (GTBP) - REGDEX SEC Filings 11/07/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/26/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 10/26/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/16/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 10/16/2006
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 10/16/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/21/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 09/21/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 08/15/2006
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 08/14/2006
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 08/02/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/26/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 07/26/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 06/30/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/29/2006
GT Biopharma, Inc. (GTBP) - ARS SEC Filings 06/21/2006
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 06/15/2006
GT Biopharma, Inc. (GTBP) - PRER14A SEC Filings 06/09/2006
GT Biopharma, Inc. (GTBP) - CORRESP SEC Filings 06/09/2006
GT Biopharma, Inc. (GTBP) - UPLOAD SEC Filings 06/07/2006
GT Biopharma, Inc. (GTBP) - PRE 14A SEC Filings 06/05/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 06/01/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/31/2006
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 05/23/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 05/15/2006
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 05/12/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/10/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 04/13/2006
GT Biopharma, Inc. (GTBP) - POS AM SEC Filings 04/05/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/04/2006
GT Biopharma, Inc. (GTBP) - 10KSB SEC Filings 03/31/2006
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 03/23/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/21/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 03/21/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 03/15/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/14/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 02/16/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/15/2006
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/14/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 02/13/2006
GT Biopharma, Inc. (GTBP) - 8-K/A - Current report SEC Filings 02/10/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/10/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 01/10/2006
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 01/10/2006
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/04/2006
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 01/04/2006
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/30/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/08/2005
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 12/08/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/23/2005
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 11/23/2005
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 11/15/2005
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 11/14/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/02/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/07/2005
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 10/07/2005
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 10/07/2005
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 09/26/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/23/2005
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 08/16/2005
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 08/15/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/04/2005
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 06/23/2005
GT Biopharma, Inc. (GTBP) - 10KSB/A SEC Filings 06/16/2005
GT Biopharma, Inc. (GTBP) - 10QSB/A SEC Filings 06/15/2005
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 05/27/2005
GT Biopharma, Inc. (GTBP) - 10QSB/A SEC Filings 05/26/2005
GT Biopharma, Inc. (GTBP) - SB-2/A SEC Filings 05/25/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/25/2005
GT Biopharma, Inc. (GTBP) - DEFA14A SEC Filings 05/24/2005
GT Biopharma, Inc. (GTBP) - SB-2/A SEC Filings 05/18/2005
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 05/13/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/03/2005
GT Biopharma, Inc. (GTBP) - SB-2/A SEC Filings 04/29/2005
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 04/29/2005
GT Biopharma, Inc. (GTBP) - REGDEX SEC Filings 03/11/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/04/2005
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 03/02/2005
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 03/02/2005
GT Biopharma, Inc. (GTBP) - SB-2 SEC Filings 02/25/2005
GT Biopharma, Inc. (GTBP) - 10KSB SEC Filings 02/25/2005
GT Biopharma, Inc. (GTBP) - SC 13G/A SEC Filings 02/11/2005
GT Biopharma, Inc. (GTBP) - 8-K/A - Current report SEC Filings 02/10/2005
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 01/25/2005
GT Biopharma, Inc. (GTBP) - REGDEX SEC Filings 01/21/2005
GT Biopharma, Inc. (GTBP) - REGDEX SEC Filings 01/14/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/10/2005
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 01/07/2005
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/04/2005
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/27/2004
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/14/2004
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 11/12/2004
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/19/2004
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 10/13/2004
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/24/2004
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 08/23/2004
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/10/2004
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 08/06/2004
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 07/23/2004
GT Biopharma, Inc. (GTBP) - 4/A SEC Filings 06/30/2004
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 06/29/2004
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/10/2004
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/28/2004
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 05/14/2004
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 04/29/2004
GT Biopharma, Inc. (GTBP) - 4/A SEC Filings 04/26/2004
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 04/26/2004
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 04/26/2004
GT Biopharma, Inc. (GTBP) - SC 14F1 SEC Filings 04/15/2004
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/31/2004
GT Biopharma, Inc. (GTBP) - 10KSB SEC Filings 03/26/2004
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/15/2004
GT Biopharma, Inc. (GTBP) - S-8 SEC Filings 03/11/2004
GT Biopharma, Inc. (GTBP) - SC 13D/A SEC Filings 03/10/2004
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 01/20/2004
GT Biopharma, Inc. (GTBP) - SC 13D SEC Filings 01/16/2004
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/30/2003
GT Biopharma, Inc. (GTBP) - 4/A SEC Filings 12/11/2003
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/11/2003
GT Biopharma, Inc. (GTBP) - 4/A SEC Filings 12/09/2003
GT Biopharma, Inc. (GTBP) - 4/A SEC Filings 12/08/2003
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 12/08/2003
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/20/2003
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 11/14/2003
GT Biopharma, Inc. (GTBP) - 4/A SEC Filings 10/24/2003
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 10/24/2003
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 08/15/2003
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 08/14/2003
GT Biopharma, Inc. (GTBP) - 4 SEC Filings 08/06/2003
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/18/2003
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/16/2003
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 05/15/2003
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 04/30/2003
GT Biopharma, Inc. (GTBP) - S-8 SEC Filings 04/24/2003
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/15/2003
GT Biopharma, Inc. (GTBP) - 10KSB SEC Filings 03/31/2003
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 11/14/2002
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 08/14/2002
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/19/2002
GT Biopharma, Inc. (GTBP) - 10QSB SEC Filings 05/15/2002
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 04/29/2002
GT Biopharma, Inc. (GTBP) - 10KSB SEC Filings 04/01/2002
GT Biopharma, Inc. (GTBP) - SC 13D SEC Filings 03/22/2002
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 03/22/2002
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/19/2002
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/22/2002
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/14/2001
GT Biopharma, Inc. (GTBP) - SC 13G SEC Filings 08/14/2001
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/14/2001
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/2001
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/23/2001
GT Biopharma, Inc. (GTBP) - S-8 SEC Filings 01/30/2001
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 01/16/2001
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/29/2000
GT Biopharma, Inc. (GTBP) - S-3/A SEC Filings 12/21/2000
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/14/2000
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 11/09/2000
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/14/2000
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 07/07/2000
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/12/2000
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/12/2000
GT Biopharma, Inc. (GTBP) - 3 SEC Filings 03/30/2000
GT Biopharma, Inc. (GTBP) - 10-K405 - Current report SEC Filings 03/30/2000
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/23/2000
GT Biopharma, Inc. (GTBP) - S-8 SEC Filings 03/10/2000
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/29/1999
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/15/1999
GT Biopharma, Inc. (GTBP) - DEFR14A SEC Filings 10/19/1999
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/12/1999
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 07/16/1999
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/13/1999
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/14/1999
GT Biopharma, Inc. (GTBP) - 10-K/A - Current report SEC Filings 04/30/1999
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/30/1999
GT Biopharma, Inc. (GTBP) - S-3/A SEC Filings 11/12/1998
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/12/1998
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 10/27/1998
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 09/21/1998
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 08/21/1998
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/07/1998
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 07/06/1998
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 06/09/1998
GT Biopharma, Inc. (GTBP) - PRER14A SEC Filings 05/28/1998
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/1998
GT Biopharma, Inc. (GTBP) - PRER14A SEC Filings 05/08/1998
GT Biopharma, Inc. (GTBP) - PRE 14A SEC Filings 03/30/1998
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/30/1998
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/26/1998
GT Biopharma, Inc. (GTBP) - 8-K/A - Current report SEC Filings 03/12/1998
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/15/1998
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/12/1997
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/13/1997
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/02/1997
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/14/1997
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/01/1997
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 04/21/1997
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 04/04/1997
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/31/1997
GT Biopharma, Inc. (GTBP) - PRE 14A SEC Filings 03/19/1997
GT Biopharma, Inc. (GTBP) - SC 13D SEC Filings 12/31/1996
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 12/30/1996
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 12/17/1996
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/13/1996
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 11/04/1996
GT Biopharma, Inc. (GTBP) - S-3/A SEC Filings 08/27/1996
GT Biopharma, Inc. (GTBP) - S-3/A SEC Filings 08/22/1996
GT Biopharma, Inc. (GTBP) - 10-K/A - Current report SEC Filings 08/22/1996
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/12/1996
GT Biopharma, Inc. (GTBP) - S-3/A SEC Filings 07/30/1996
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/21/1996
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 06/13/1996
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 05/24/1996
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/15/1996
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 05/06/1996
GT Biopharma, Inc. (GTBP) - PRE 14A SEC Filings 04/12/1996
GT Biopharma, Inc. (GTBP) - 10-K - Current report SEC Filings 03/29/1996
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 03/15/1996
GT Biopharma, Inc. (GTBP) - 424B3 SEC Filings 01/16/1996
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 01/03/1996
GT Biopharma, Inc. (GTBP) - S-8 SEC Filings 11/20/1995
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 11/14/1995
GT Biopharma, Inc. (GTBP) - 8-K/A - Current report SEC Filings 09/29/1995
GT Biopharma, Inc. (GTBP) - S-3/A SEC Filings 08/30/1995
GT Biopharma, Inc. (GTBP) - 10-K/A - Current report SEC Filings 08/30/1995
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 08/14/1995
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 08/03/1995
GT Biopharma, Inc. (GTBP) - 10-C SEC Filings 07/28/1995
GT Biopharma, Inc. (GTBP) - DEF 14A SEC Filings 07/21/1995
GT Biopharma, Inc. (GTBP) - S-3 SEC Filings 07/18/1995
GT Biopharma, Inc. (GTBP) - 8-K - Current report SEC Filings 06/08/1995
GT Biopharma, Inc. (GTBP) - 10-C SEC Filings 06/08/1995
GT Biopharma, Inc. (GTBP) - 10-Q - Quarterly Report SEC Filings 05/12/1995

Press Releases

StockPrice Release
Gt biopharma appoints new member to its board of directors 06/13/2025
Gt biopharma advances gtb-3650 phase 1 trial to cohort 2 following successful initial human dosing and evidence of early immune activation signals 05/19/2025
Gt biopharma appoints new member to its board of directors 05/14/2025
Gt biopharma announces exercise of warrants 02/25/2025
Gt biopharma reports third quarter 2024 financial results 11/14/2024
Gt biopharma to participate in the 3rd annual roth healthcare opportunities conference 09/26/2024
Gt biopharma to host virtual kol event showcasing its nk cell engager pipeline and broad indication potential on october 10, 2024 09/24/2024
Gt biopharma announces fda clearance of investigational new drug (ind) application for gtb-3650, an nk cell engager for treatment of cd33+ leukemia 06/27/2024
Gt biopharma, inc. announces $3.2 million registered direct offering priced at-the-market under nasdaq rules 05/21/2024
Gt biopharma reports first quarter 2024 financial results and provides corporate update 05/15/2024
Gt biopharma reports fourth quarter and full-year 2023 financial results 03/26/2024
Gt biopharma, inc. announces 1-for-30 reverse stock split 02/01/2024
Leading proxy advisory firms, iss and glass lewis, recommend gt biopharma stockholders vote “for” all proposed items at the upcoming special meeting of stockholders 12/06/2023
Gt biopharma announces ind submission for gtb-3650 for treatment of cd33+ leukemia 12/04/2023
Gt biopharma presented positive preclinical data for gtb-5550, a novel trike® molecule for targeted prostate cancer treatment during the society for immunotherapy of cancer (sitc) 2023 annual meeting 11/06/2023
Gt biopharma reports third quarter 2023 financial results 11/01/2023
Gt biopharma reports second quarter 2023 financial results 08/07/2023
Gt biopharma to participate in the h.c. wainwright immune cell engager conference on august 17, 2023 08/03/2023
Gt biopharma reports first quarter 2023 financial results and provides corporate update 05/15/2023
Gt biopharma names charles j. casamento to the board of directors 05/04/2023
Gt biopharma reports fourth quarter and full-year 2022 financial results and provides corporate update 03/30/2023
Gt biopharma to participate in the h.c. wainwright cell therapy virtual conference 02/24/2023
Gt biopharma issues open letter to shareholders detailing recent activities 02/02/2023
Gt biopharma, inc. announces $6.5 million registered direct offering priced at premium to market 12/30/2022
Gt biopharma names dr. jeff miller as consulting chief medical officer 12/14/2022
Gt biopharma and fate therapeutics present preclinical data highlighting novel dual antigen targeting approach for the treatment of aml at ash 2022 12/12/2022
Gt biopharma presents two posters at the society for immunotherapy of cancer's (sitc) 37th annual meeting 11/10/2022
Gt biopharma reports third quarter fiscal 2022 financial results and business update 10/31/2022
Gt biopharma presents at ld micro on october 26, 2022 at 4:30 pm pst 10/25/2022
Gt biopharma announces adjournment of special shareholders meeting 10/04/2022
Gt biopharma poster presentation and mini oral session at esmo congress 2022 demonstrates gtb-5550 trike® ability to specifically target and efficiently kill multiple b7h3+ solid and hematologic malignancies 09/12/2022
Gt biopharma to participate in the h.c. wainwright 24th annual global investment conference in september 09/08/2022
Gt biopharma affirms manufacturing timeline for lead investigational asset gtb-3650 08/30/2022
Gt biopharma reports second quarter fiscal 2022 financial results and business update 08/11/2022
Gt biopharma presents preclinical data demonstrating second-generation cd19 targeting tri-specific killer engager (trike®) driving robust nk cell function against b cell malignancies at eha 2022 congress 06/10/2022
Gt biopharma reports first quarter fiscal 2022 financial results and business update 05/16/2022
Gt biopharma to participate at h.c. wainwright hybrid global investment conference 05/12/2022
Gt biopharma presents preclinical data demonstrating novel b7h3+ tumor targeting gtb-5550 trike® driving nk cell activation and adcc against head and neck squamous cell carcinomas at aacr annual meeting 2022 04/11/2022
Gt biopharma reports fourth quarter and full-year 2021 financial results and provides corporate update 03/28/2022
Gt biopharma presents trike® nanobody pipeline (gtb-5550) preclinical multiple myeloma proof-of-concept data at 2022 ebmt annual meeting 03/21/2022
Gt biopharma presented preclinical data demonstrating novel mesothelin-targeted trike® driving cytotoxicity across all stages of non-small cell lung cancer at esmo tat 2022 03/09/2022
Gt biopharma to participate in-person at 34th annual roth conference, march 13-15, 2022 03/03/2022
Gt biopharma to present pre-clinical data at upcoming medical conferences 02/24/2022
Gt biopharma appoints manu ohri as chief financial officer 02/18/2022
Gt biopharma to present at b. riley securities' virtual oncology conference 01/20/2022
Gt biopharma demonstrates novel b7-h3 targeting dual camelid nanobody bike and gtb-5550 induce nk cell activation against broad spectrum of tumors at esmo io congress 2021 12/08/2021
Gt biopharma abstract on novel b7-h3 immune checkpoint targeting broad spectrum solid and hematologic malignancies accepted for presentation at esmo io congress 2021 11/30/2021
Gt biopharma announces executive leadership transition to implement next phase of strategic journey 11/08/2021
Gt biopharma's next generation camelid trike® nanobody platform highlighted at esmo congress 2021 09/20/2021
Gt biopharma announces updated positive safety data from phase 1 gtb-3550 monotherapy trike™ trial an investigational immunotherapy for refractory cancers to be presented at esmo congress 2021 09/15/2021
Gt biopharma advances gtb-3650, a second-generation tri-specific killer engager -trike®, into ind-enabling studies 09/13/2021
Gt biopharma to present at upcoming september investor conferences 09/08/2021
Gt biopharma announces the promotion of dr. gregory berk to president of research & development and chief medical officer 08/23/2021
Gt biopharma provides second quarter 2021 business update 08/13/2021
Gt biopharma announces sponsored research agreement with dr. jeffrey s. miller of the university of minnesota 07/07/2021
Gt biopharma ceo, tony cataldo to present at sir anthony ritossa's global family office investment summit 06/24/2021
Gt biopharma announces interim gtb-3550 trike™ monotherapy clinical trial results at 2021 raymond james human health innovation conference 06/23/2021
Gt biopharma to present at raymond james human health innovation conference 06/16/2021
Gt biopharma to be added to the russell 2000® index 06/08/2021
Gt biopharma to host interim gtb-3550 trike™ data review call with dr. jeffrey s. miller on may 19, 2021 at 4:00 pm et 05/18/2021
Gt biopharma reports first quarter 2021 results 05/17/2021
Gt biopharma announces update on the commencement of the gtb-3550 trike™ monotherapy phase 2 clinical trial and solid tumor trike™ product candidates 05/12/2021
Gt biopharma announces the appointments of gregory berk, m.d. to chief medical officer and jeffrey s. 04/26/2021
Gt biopharma reports fourth quarter and year end 2020 results and business update 04/19/2021
Gt biopharma announces gtb-3550 trike™ monotherapy rescues and restores nk cell immune surveillance in relapsed/refractory aml and mds cancer patients 04/12/2021
Gt biopharma announces enrollment of patient 10 in gtb-3550 trike™ phase i/ii clinical trial 04/08/2021
Gt biopharma's trike™ interim clinical trial results presented at innate killer summit 2021 03/29/2021
Gt biopharma announces updated interim gtb-3550 trike™ clinical trial results 03/17/2021
Gt biopharma announces closing of $23.7 million public offering 02/16/2021
Gt biopharma announces pricing of $23,650,000 public offering and uplisting to the nasdaq capital market 02/11/2021
Gt biopharma announces trike™ for the treatment of breast and gi cancers 12/28/2020
Gt biopharma announces fda data - gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient 12/21/2020
Gt biopharma and cytovance biologics announce milestone achievement 12/17/2020
Gt biopharma submits application for uplisting to the nasdaq capital market 12/14/2020

More Headlines

News
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024. 06/27/2024
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company's common stock at a purchase price of $4.35 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue warrants to purchase up to 740,000 shares of common stock. The warrants have an exercise price of $4.35 per share, will be exercisable immediately and will have a term of five years following the date of issuance. The closing of the offering is expected to occur on or about May 23, 2024, subject to the satisfaction of customary closing conditions. 05/21/2024
What made GT Biopharma stock more than double on Monday? GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn't been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company. 05/20/2024
Why Is GT Biopharma (GTBP) Stock Up 143% Today? GT Biopharma (NASDAQ: GTBP ) stock is soaring higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 10.6 million shares of GTBP stock changing hands as of this writing. 05/20/2024
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update BRISBANE, CALIFORNIA, May 15, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter 2024 financial results for the period ended March 31, 2024. 05/15/2024
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2023 results for the period ended December 31, 2023. 03/26/2024
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, announced today that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol “GTBP” and will begin trading on a post-split basis at the market open on February 5, 2024. The CUSIP number for the common stock following the reverse stock split will be 36254L 308. The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. 02/01/2024
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (Nasdaq: GTBP) (the “Company”), announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended GT Biopharma stockholders entitled to vote at the Company's 2023 Special Meeting of Stockholders (the “Special Meeting”) to vote “ FOR ” Proposal items number 1 and 2. If approved, Proposal No. 1. will provide the Company's Board of Directors (the “Board”) with the option to implement a reverse stock split of the Company's issued and outstanding common stock (the “Reverse Split”), if deemed necessary in the future, to maintain the Company's listing on the Nasdaq Capital Market (“Nasdaq”). 12/06/2023
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of GTB-3650, a 2nd generation nanobody TriKE® for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). 12/04/2023
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced positive preclinical data in highlighting GTB-5550's potential in prostate cancer. Martin Felices, PhD, Associate Professor of Medicine at the University of Minnesota, presented these data on Saturday, November 4th at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, which is being held in San Diego, California November 1-5. 11/06/2023
GT Biopharma Reports Third Quarter 2023 Financial Results BRISBANE, CALIFORNIA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced third quarter 2023 results for the period ended September 30, 2023. 11/01/2023
GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. 08/24/2023
GT Biopharma Reports Second Quarter 2023 Financial Results C ash of approximately $ 1 8.0 million as of June 30 , 202 3 , provide s ample runway to fund operations into Q 3 202 4; anticipated to b e sufficient to achieve IND clearance for GTB-3650 and initiate clinical trial activit ies on GTB-3650. 08/07/2023
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023 BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Dr. Jeffrey Miller, MD, GT Biopharma's Consulting Chief Medical Officer and Consulting Chief Scientific Officer, will participate in a fireside chat and the Keynote Session: KOL roundtable discussion at H.C. Wainwright's Immune Cell Engager Conference taking place August 17, 2023. Company management will also be participating in 1x1 meetings during the event. 08/03/2023
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. 06/02/2023
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 05/19/2023
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Dr. Jeffrey Miller, MD, GT Bipharma's Consulting Chief Medical Officer and Chief Scientific Officer, will present a corporate overview at H.C. Wainwright's Cell Therapy Virtual Conference taking place on February 28, 2023. Company management will also be participating in 1x1 meetings during the event. 02/24/2023
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced the presentation of new data at the American Society of Hematology’s 64th Annual Meeting… The post GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming... 11/03/2022
GT Biopharma Announces Adjournment of Special Shareholders Meeting – Meeting adjourned to October 10, 2022 at 11 a.m. PST– GTB encourages all stockholders of record on August 8, 2022 who have not yet voted– to do so by 11:59 p.m. PST Time on October 9, 2022 BRISBANE, CALIFORNIA, Oct. 04, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP),… The post GT Biopharma Announces Adjournment of Special Shareholders Meeting appeared first on DKODING... 10/04/2022
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that management will present in-person at H.C. Wainwright's 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace. Company management will also be participating in 1x1 meetings during the event. 09/08/2022
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that management will present at H.C. Wainwright's Hybrid Global Investment Conference. The conference will take place May 23-26, 2022 at the Fontainebleau, Miami Beach Hotel, Miami Beach, Florida. 05/12/2022
GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences: Abstract and poster presentation details are as follows: ESMO Targeted Anticancer Therapies Congress (TAT) (March 7-8, 2022) Title: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE) Abstract Number: 250 Session: Immunotherapy Presentation Type: Poster Session Date and Time: March 7, 9:20AM (CET) (On-demand e-poster display) Location: Virtual Poster Board Number: 17P 48th Annual European Society for Blood and Marrow Transplantation (EBMT) (March 19-23, 2022) Title: A Tri-specific Killer Engager (TriKE) against B7-H3 enhances NK cell mediated killing of multiple myeloma Abstract Number: AS-EBMT-2022-00508 Session: New Drugs- and Cell-Based Immune Therapies Presentation Type: Poster Session Date and Time: March 19, 2022, 9:50 AM (CET) Location: Prague Congress Center, Czech Republic Poster Board Number: P153 American Association for Cancer Research (AACR) Annual Meeting (April 8-13, 2022) Title: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas Abstract Number: Abstract control number 3334, permanent abstract number 3435 Session: Clinical Research Excluding Trials, Combination Immunotherapies / Therapeutic Antibodies Presentation Type: Poster Session Date and Time: April 12, 2022 1:30 PM – 5:00 PM Location: Ernest N. 02/24/2022
GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B. 01/20/2022
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness 11/15/2021
GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021 BEVERLY HILLS, Calif., Sept. 20, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced Dr. Jeffrey Miller's mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021. 09/20/2021
OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 09/16/2021
GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021 BEVERLY HILLS, Calif., Sept. 15, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE protein biologic technology platform, today announced that Jeffrey Miller, MD, University of Minnesota Medical School, Professor of Medicine, Division of Hematology, Oncology and Transportation will present a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 to be held virtually September 16-21. 09/15/2021
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies BEVERLY HILLS, Calif., Sept. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today, announces the advancement of GTB-3650 into IND-enabling studies, with which it plans to supplant the ongoing Phase 1 program with GTB-3550. 09/13/2021
GT Biopharma to Present at Upcoming September Investor Conferences BEVERLY HILLS, Calif., Sept. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that Anthony Cataldo, Chairman & CEO, Dr. Greg Berk, President of R&D and Chief Medical Officer, and Dr. Jeff Miller, Consulting Chief Scientific Officer will be presenting and hosting one-on-one meetings at the upcoming H.C. 09/08/2021
GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer BEVERLY HILLS, Calif., Aug. 23, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, today announced the promotion of Gregory Berk, M.D. 08/23/2021
GT Biopharma, Inc. (GTBP) CEO Tony Cataldo on Q2 2021 Results - Earnings Call Transcript GT Biopharma, Inc. (GTBP) CEO Tony Cataldo on Q2 2021 Results - Earnings Call Transcript 08/13/2021
GT Biopharma Provides Second Quarter 2021 Business Update BEVERLY HILLS, Calif., Aug. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE®) protein biologic technology platform, today provided a general business update of events in the second quarter ending June 30, 2021. 08/13/2021
Former Penny Stocks To Watch After Merck's (MRK) Latest FDA Win Merck's FDA and coronavirus vaccine news sparked momentum in biotech stocks today. Here are 4 to watch. 08/12/2021
Hot Biotech Stocks That Deserve Your Attention In August 2021 Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 08/11/2021
Are Penny Stocks Worth It? 5 That Deserve Your Attention Now Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It? 08/05/2021
GTBP Stock Price Increases Over 6% Pre-Market: Why It Happened The stock price of GT Biopharma, Inc. (NASDAQ: GTBP) increased by over 6% pre-market. This is why it happened. 08/03/2021
Former Biotech Penny Stocks Seeing Explosive Moves In 2021 Are penny stocks worth it? Take a look at these 3 seeing explosive moves this year. 08/02/2021
3 Biotech Penny Stocks To Watch On Robinhood IPO Day These Former Penny Stocks Are Turning Heads Ahead Of Robinhood IPO The post 3 Biotech Penny Stocks To Watch On Robinhood IPO Day appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 07/29/2021
3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 07/23/2021
3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 Are biotech penny stocks on your watch list in 2021? The post 3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 07/21/2021
Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech Penny Stocks & Small Caps Jump As Biotech Industry Names Kick Into High Gear The post Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 07/19/2021
4 Hot Penny Stocks To Watch After The 1,100% SGOC Stock Rally Are traders searching for penny stocks with certain technical traits like SGOC has? The post 4 Hot Penny Stocks To Watch After The 1,100% SGOC Stock Rally appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 07/12/2021
3 Former Penny Stocks To Watch This Week As Earnings Season Kicks Off Why Focus On Penny Stocks? Here Are A Few That Give A Great Answer To That Question. 07/12/2021
GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota Deepening relationship between GT Biopharma and Dr. Jeffrey Miller TriKE™ improves FT538 iPSC NK cells from Fate Therapeutics in prostate cancer model GTB-3550 continues to demonstrate clinical success without significant toxicities BEVERLY HILLS, Calif., July 7, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform, announced it has entered into a sponsored research agreement (SRA) with Jeffrey S. 07/07/2021
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July Looking for biotech penny stocks to watch right now? Here are 7 for your list this week. 07/05/2021
Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now Current & former penny stocks to watch if you like biotech right now. The post Best Penny Stocks For Your July 2021 List? 06/30/2021
7 Hot Penny Stocks Analysts Like To Watch In 2021 Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 06/28/2021
9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290% Do you agree with analysts on these penny stocks? The post 9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290% appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 06/24/2021
GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit BEVERLY HILLS, Calif, June 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that GT Biopharma CEO, Tony Cataldo will be presenting as a VIP speaker at the upcoming Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021. The Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco is one of a series of international summits held annually as a platform for exceptional networking between Family Offices and Thought Leaders from all over the world. 06/24/2021
8 Hot Biotech Penny Stocks For Your July 2021 Watch List Current & Former Penny Stocks To Watch Before July The post 8 Hot Biotech Penny Stocks For Your July 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 06/23/2021
GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference BEVERLY HILLS, Calif., June 23, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform, announced Jeffrey S. 06/23/2021
3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021 These former penny stocks have followed the path of AMC stock this month The post 3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 06/16/2021
GT Biopharma to Present at Raymond James Human Health Innovation Conference BEVERLY HILLS, Calif., June 16, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it will provide a corporate update at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET. 06/16/2021
4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021 If biotech penny stocks are your focus, check these 4 out right now The post 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 06/14/2021
4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now Are these former penny stocks on your watch list right now? The post 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 06/11/2021
GT Biopharma to be Added to the Russell 2000® Index BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021. 06/08/2021
Hot Penny Stocks To Watch As AMC Stock Ignites Small Caps In June AMC stock ignites momentum in small cap penny stocks this month. The post Hot Penny Stocks To Watch As AMC Stock Ignites Small Caps In June appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 06/07/2021
3 Penny Stocks To Watch Right Now As Meme Stocks AMC & BB Soar Penny stocks are red hot this year & it isn't just because of meme momentum. The post 3 Penny Stocks To Watch Right Now As Meme Stocks AMC & BB Soar appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 06/02/2021
Reddit Penny Stocks You Might've Missed In May 2021 Former penny stocks on Reddit you might've overlooked this month The post Reddit Penny Stocks You Might've Missed In May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/27/2021
Are Penny Stocks Worth It? 3 Cheap Stocks To Watch Before June 2021 GameStop (NYSE:GME) Is Surging Bringing Validity To Countless Penny Stocks Right Now The post Are Penny Stocks Worth It? 3 Cheap Stocks To Watch Before June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/26/2021
Trading Penny Stocks? 3 Biotech Stocks To Watch Before June 2021 Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks? 05/25/2021
Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021 Penny stocks that left the nest in 2021 To Watch Right Now The post Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/20/2021
5 Penny Stocks To Watch Right Now That Analysts Are Bullish On Penny stocks remain volatile but these analysts have a bright outlook on these The post 5 Penny Stocks To Watch Right Now That Analysts Are Bullish On appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/18/2021
GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET BEVERLY Hills, Calif., May 18, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology, TriKE™, for the treatment of cancer and infectious diseases, today announced that it will be hosting a call with Dr. Jeffrey S. 05/18/2021
GT Biopharma Reports First Quarter 2021 Results BEVERLY HILLS, Calif., May 17, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today reported financial results for the first quarter ended March 31, 2021 and provided a general business update. 05/17/2021
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know OXIS International Inc. (GTBP) closed the most recent trading day at $12.51, moving +1.54% from the previous trading session. 05/17/2021
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect? GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result. 05/13/2021
Former Penny Stocks To Watch Making Their Mark In 2021 These penny stocks hit it out of the park in 2021 & continue to climb in May. The post Former Penny Stocks To Watch Making Their Mark In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/12/2021
GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:… The post GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/12/2021
GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform, is pleased to provide an update concerning the commencement of the GTB-3550 TriKE™ monotherapy Phase 2 clinical trial, and certain of its solid tumor targeting TriKE™ product candidates. 05/12/2021
Former Penny Stocks To Watch Making New Highs In May 2021 Penny stocks are hot right now and these former low-priced names are reaching for new highs this month. The post Former Penny Stocks To Watch Making New Highs In May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/03/2021
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know In the latest trading session, OXIS International Inc. (GTBP) closed at $11.74, marking a +0.34% move from the previous day. 04/28/2021
3 Penny Stocks To Watch As Biotech Surges In April 2021 These biotech penny stocks have begun turning heads in April 2021 The post 3 Penny Stocks To Watch As Biotech Surges In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 04/26/2021
GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D. 04/26/2021
Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus List Of Penny Stocks To Watch Right Now The post Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 04/21/2021
GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, reported financial results for the fourth quarter and year ended December 31, 2020. 04/19/2021
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform, is pleased to announce the enrollment of Patient 10 in its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML). 04/08/2021
GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021 BEVERLY HILLS, Calif., March 29, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform is pleased to announce that Dr. Jeffrey S. 03/29/2021
GT Biopharma's GTB-3550 Cuts Bone Marrow Blasts In High-Risk Patients With Hematological Malignancies GT Biopharma Inc (NASDAQ: GTBP) has reported updated interim data from Phase 1/2 clinical trial, evaluating the Company's lead candidate, GTB-3550, in high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML). To date, nine patients have been enrolled in the trial. 03/17/2021
GTBP Stock Price Increases Over 3% Pre-Market: Why It Happened The stock price of GT Biopharma, Inc. (NASDAQ: GTBP) has increased by over 3% pre-market. This is why it happened. 03/17/2021
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results BEVERLY HILLS, Calif., March 17, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform is pleased to announce updated interim Phase I/II clinical trial results for the Company's lead therapeutic candidate, GTB-3550, being evaluated for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML). 03/17/2021
GTBP Stock Price Increases Over 150% Pre-Market: Why It Happened The stock price GT Biopharma Inc (NASDAQ: GTBP) increased by over 150% pre-market. This is why it happened. 03/09/2021
GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform is pleased to announce the presentation of additional... 12/21/2020
GT Biopharma And Cytovance Biologics Announce Milestone Achievement BEVERLY HILLS, Calif., Dec. 17, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™) platform, announced today that Cytovance, a USA-based contract development... 12/17/2020
GT Biopharma Submits Application for Uplisting to the NASDAQ Capital Market BEVERLY HILLS, Calif., Dec. 14, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform today announced that it has submitted an application... 12/14/2020
7 Biotech Penny Stocks Worth a Gamble With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Penny Stocks Worth a Gamble appeared first on InvestorPlace. 11/11/2020

Unlock

GTBP Ratings Summary

GTBP Quant Ranking